Fig. 1From: Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies124-I-omburtamab whole-body positron emission tomography (PET) scans obtained approximately 4Â h, 24Â h and 48Â h following a single injection of 74Â MBq intraventricular 124-I-omburtamab, demonstrating activity throughout the ventricles, the sac and over the convexitiesBack to article page